Achieve Life Sciences, Inc.
ACHV- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
In the last 90 days, Achieve Life Sciences, Inc. insiders filed 0 open-market purchases and 1 sale; 111 institutions reported holding it in 13F filings for Q2 2026, worth $538.7M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Achieve Life Sciences, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 31 | 28 | −3 |
| Shares | 2.04M | 2.12M | +78.4K (+3.8%) |
| Value | $9.97M | $7.00M | −$2.97M (−29.8%) |
New holders (4)
Institutions that held Achieve Life Sciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 16,082 | $53.0K | 0.00% |
| Stephens Consulting, LLC | 3,000 | $9.90K | 0.01% |
| Godsey & Gibb Associates | 453 | $1.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 100 | $330 | 0.00% |
Sold out (7)
Institutions that held Achieve Life Sciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Franklin Resources Inc | 23,536 | $115.0K |
| Oppenheimer & Co Inc | 21,300 | $104.0K |
| Acadian Asset Management LLC | 3,704 | $18.0K |
| Simplex Trading, LLC | 2,248 | $10.0K |
| UBS Group AG | 1,077 | $5.00K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 480 | $2.00K |
| Newbridge Financial Services Group, Inc. | 308 | $2.00K |